Edition:
United States

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

10.35USD
24 Sep 2018
Change (% chg)

-- (--)
Prev Close
$10.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
212,571
52-wk High
$31.42
52-wk Low
$6.99

Latest Key Developments (Source: Significant Developments)

Dermira Qtrly Loss Per Share $‍1.34​
Thursday, 22 Feb 2018 04:01pm EST 

Feb 22 (Reuters) - Dermira Inc ::DERMIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.DERMIRA INC - ‍OLUMACOSTAT GLASARETIL TOPLINE PHASE 3 DATA EXPECTED Q1 2018​.DERMIRA INC QTRLY LOSS PER SHARE $‍1.34​.DERMIRA INC QTRLY ‍COLLABORATION AND LICENSE REVENUE $1.3 MILLION VERSUS $22.5 MILLION​.  Full Article

Dermira Initiates Mid-Stage Study Testing Eczema Treatment
Wednesday, 31 Jan 2018 08:30am EST 

Jan 31 (Reuters) - Dermira Inc ::DERMIRA INITIATES PHASE 2B DOSE-RANGING STUDY EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.DERMIRA INC - ‍TOPLINE RESULTS FROM PHASE 2B DOSE-RANGING STUDY​ EXPECTED IN FIRST HALF OF 2019.  Full Article

Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate
Monday, 6 Nov 2017 04:03pm EST 

Nov 6 (Reuters) - Dermira Inc :Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis.Dermira Inc - ‍FDA decision on new drug application for glycopyrronium tosylate expected by June 30, 2018​.Dermira Inc - qtrly net loss per share, basic and diluted $4.30 ‍​.Dermira Inc - updating its financial guidance for full year 2017; now expects collaboration and license revenue of approximately $4.3 million for FY​.  Full Article

Dermira and UCB agree to end collaboration agreement for Cimzia
Monday, 6 Nov 2017 04:01pm EST 

Nov 6 (Reuters) - Dermira Inc :Dermira and UCB agree to end collaboration agreement for Cimzia.Dermira Inc - ‍Dermira to transition development and commercialization responsibility for Cimzia (Certolizumab Pegol) in psoriasis back to UCB​.Dermira Inc - ‍collaboration agreement will terminate on February 15, 2018 and companies anticipate completion of transition by such date​.Dermira Inc - ‍pursuant to collaboration agreement, there are no termination or penalty payments required by either party​.Dermira - for repurchase of all product rights, licenses and intellectual property relating to cimzia, ucb will pay to dermira $11.0 million by Nov 13.  Full Article

Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris
Thursday, 5 Oct 2017 08:00am EDT 

Oct 5 (Reuters) - Dermira Inc :Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris.Dermira Inc - Dermira expects to announce topline efficacy and safety results from CLAREOS-1 and CLAREOS-2 studies in Q1 of 2018.  Full Article

Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Dermira Inc :Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab.Dermira Inc - Initiation of a phase 2B clinical study is expected in Q1 of 2018​.Dermira Inc - ‍Plans to develop and commercialize Lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe Atopic Dermatitis​.Dermira Inc - Under terms of agreement, Dermira will make an initial payment of $80 million to Roche and payments totaling $55 million in 2018.Dermira Inc - Dermira will also be obligated to make additional payments upon achievement of certain milestones.Dermira Inc - Expects to record a charge related to acquisition of in-process research and development for a total of $135 million​.Dermira Inc - ‍Estimates it will incur up to $10 million in operating expenses in 2017 for costs related to transferring Lebrikizumab program to dermira​.Dermira Inc - cash and cash equivalents and investments would be sufficient to meet its anticipated cash requirements into first half of 2019.Dermira Inc - Dermira anticipates that it will spend approximately $200 million to obtain topline results for phase 2B study.  Full Article

Dermira Q2 qtrly ‍net loss per share $0.93​
Monday, 7 Aug 2017 04:05pm EDT 

Aug 7 (Reuters) - Dermira Inc ::Dermira reports second quarter 2017 financial results and provides corporate update.Dermira Inc qtrly ‍net loss per share, basic and diluted, $0.93​.Dermira - ‍as of June 30, co had cash, cash equivalents and short- and long-term investments of $695.9 million and 41.6 million common shares outstanding​.Dermira Inc - ‍reiterates its previously issued financial guidance for full year 2017​.Dermira Inc - ‍for glycopyrronium tosylate, management anticipates submission of NDA to and communication from FDA will both occur in H2 of 2017​.  Full Article

UCB and Dermira announce US and EU regulatory submissions for Cimzia
Tuesday, 25 Jul 2017 01:15am EDT 

July 25 (Reuters) - UCB SA ::UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS.  Full Article

Dermira prices offering of $250 million of 3 pct convertible senior notes
Wednesday, 10 May 2017 09:33pm EDT 

May 10 (Reuters) - Dermira Inc :Dermira prices offering of $250 million of 3.00% convertible senior notes.Pricing of its offering of $250,000,000 aggregate principal amount of 3.00% convertible senior notes due 2022.Notes will be senior, unsecured obligations of Dermira, and interest of 3.00% per year will be payable semi-annually in arrears.  Full Article

Dermira announces proposed offering of $250 mln of convertible senior notes
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Dermira Inc :Dermira announces proposed offering of $250 million of convertible senior notes.Dermira - Intends to offer, subject to market conditions and other factors, $250 million aggregate principal amount of convertible senior notes due 2022.  Full Article

Photo

FDA approves Dermira's wipe for excessive armpit sweating

Dermira Inc said on Friday its topical cloth for excessive armpit sweating was approved by the U.S. Food and Drug Administration, providing patients with an easy-to-use option for an often embarrassing condition.